Evaluation of the <scp>SD</scp> bioline cholera rapid diagnostic test during the 2016 cholera outbreak in Lusaka, Zambia

Mwaba, John; Ferreras, Eva; Chizema-Kawesa, Elizabeth; Mwimbe, Daniel; Tafirenyika, Francis; Rauzier, Jean; Blake, Alexandre; Rakesh, Ankur; Poncin, Marc; Stoitsova, Savina; Kwenda, Geoffrey; Azman, Andrew S.; Chewe, Orbrie; Serafini, Micaela; Lukwesa-Musyani, Chileshe; Cohuet, Sandra; Quilici, M; Luquero, Francisco J.; Page, Anne Laure

doi:10.1111/tmi.13084

Cited by 19 publications

(33 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous qualitative studies showed that economic burden due to MDR-TB treatment was a reason for low enrollment26,27 and treatment interruption 6. Another study found that financial support motivated patients to improve adherence28 and had a positive effect on successful treatment 5. Therefore, revising the national essential drug list and preparing a special budget to universally cover all drugs in the list, including injection fees, may be beneficial to optimize treatment regimens and improve adherence.…”

Section: Discussionmentioning

confidence: 99%

“…To our knowledge, only four studies have reported data on treatment interruption among patients with MDR-TB 3–6. Treatment interruption was defined as an interruption of any anti-TB drug for at least one day at any time during the treatment course while a serious treatment interruption lasting for more than two consecutive weeks but less than two consecutive months 3,5,6. The incidence of treatment interruption ranged from 68% to 93% and the incidence of serious interruption was 17%6 and 27%.5 Serious treatment interruption was demonstrated to be associated with unsuccessful treatment outcome 3,4.…”

Section: Introductionmentioning

confidence: 99%

“…Treatment interruption was defined as an interruption of any anti-TB drug for at least one day at any time during the treatment course while a serious treatment interruption lasting for more than two consecutive weeks but less than two consecutive months 3,5,6. The incidence of treatment interruption ranged from 68% to 93% and the incidence of serious interruption was 17%6 and 27%.5 Serious treatment interruption was demonstrated to be associated with unsuccessful treatment outcome 3,4. Only one study explored predictors of treatment interruption, which were found to be gender, education level, and directly observed treatment (DOT) coverage 6.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

<p>Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study</p>

Wang¹,

Chen²,

Huang³

et al. 2019

PPA

View full text Add to dashboard Cite

Purpose: Treatment interruption and incorrect dosage for measuring drug non-adherence have seldom been studied in multidrug-resistant tuberculosis (MDR-TB) treatment. This study aimed to 1) estimate the overall and drug-specific incidence of short (≤14 days) and serious (>14 days) treatment interruption among MDR-TB patients, 2) identify main reasons and predictors for serious interruption, and 3) document the level of agreement of classification for incorrect drug dosage between self-report and pill count. Patients and methods: A cross-sectional study combining hospital-based interviews and home-based pill count was conducted from January to June 2018. Treatment interruption was determined from patient's medical records and interviews using a structured questionnaire among 202 patients treated at one designated hospital for MDR-TB treatment. Concordance of pills counted with self-reports for each drug use within one month was assessed for a subgroup of patients at their homes using kappa statistics. Results: Of 202 patients, the incidence of short and serious treatment interruption was 37.6% and 28.7%, respectively. Adverse drug reactions (ADRs) and financial hardship were the top two reasons for serious interruption. Amikacin and cycloserine had the highest rate of specific drug interruption (18.3% and 10.2%, respectively). ADRs (OR adj : 2.82, 95% CI: 1.41-5.61), monthly out-of-pocket expenses exceeding 250 US dollars (OR adj : 2.27, 95% CI: 1.14-4.50), and baseline co-morbidities (OR adj : 2.53, 95% CI: 1.19-5.38) were significantly associated with serious treatment interruption. Of 111 patients assessed for pill count at home, 5.4% had perfect drug adherence, 54.1% had drug under-use, 6.3% had drug over-use, and 34.2% had both problems. The respective number from self-reports was 7.2%, 56.8%, 5.4% and 30.6%. The two methods gave an acceptable level of agreement for most of the drugs (kappa: 0.52-0.95). Conclusion: Close monitoring of ADRs, revision of drug regimens, and financial support for MDR-TB in this study population are needed. Self-report on drug under-use and over-use should be monitored monthly in clinical settings.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

<p>Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study</p>

Wang¹,

Chen²,

Huang³

et al. 2019

PPA

View full text Add to dashboard Cite

show abstract

“…Cholera has been present and recurring in Zambia since 1977 [ 1 ]. In Zambia and in most sub-Saharan countries, cholera is diagnosed using stool culture, serology and rapid diagnostic tests (RDTs) [ 2 ]. However, culture and RDTs do not provide the genetic relatedness or diversity information that is critical to having insight into whether the outbreaks are seeded from existing local isolates or if the outbreaks represent separate transmission events, hence, the need to have genetic data in addition to culture and RDT data.…”

Section: Introductionmentioning

confidence: 99%

Three transmission events of Vibrio cholerae O1 into Lusaka, Zambia

et al. 2021

Self Cite

View full text Add to dashboard Cite

Background Cholera has been present and recurring in Zambia since 1977. However, there is a paucity of data on genetic relatedness and diversity of the Vibrio cholerae isolates responsible for these outbreaks. Understanding whether the outbreaks are seeded from existing local isolates or if the outbreaks represent separate transmission events can inform public health decisions. Results Seventy-two V. cholerae isolates from outbreaks in 2009/2010, 2016, and 2017/2018 in Zambia were characterized using multilocus variable number tandem repeat analysis (MLVA) and whole genome sequencing (WGS). The isolates had eight distinct MLVA genotypes that clustered into three MLVA clonal complexes (CCs). Each CC contained isolates from only one outbreak. The results from WGS revealed both clustered and dispersed single nucleotide variants. The genetic relatedness of isolates based on WGS was consistent with the MLVA, each CC was a distinct genetic lineage and had nearest neighbors from other East African countries. In Lusaka, isolates from the same outbreak were more closely related to themselves and isolates from other countries than to isolates from other outbreaks in other years. Conclusions Our observations are consistent with i) the presence of random mutation and alternative mechanisms of nucleotide variation, and ii) three separate transmission events of V. cholerae into Lusaka, Zambia. We suggest that locally, case-area targeted invention strategies and regionally, well-coordinated plans be in place to effectively control future cholera outbreaks.

show abstract

“…The O139 line on this test has been reported to give false positives [ 3 , 12 , 13 ] and given that O139 rarely circulates, its inclusion in the test may be more of a nuisance than an asset. The SD Bioline O1 test has demonstrated field sensitivity of 81.1%–90.9% and specificity of 92.8%–95.2% when performed directly, with increases in both after enrichment [ 14 , 15 ]. Both the Crystal VC and SD Bioline tests detect the lipopolysaccharides (LPS) antigens of V. cholerae using the precoated monoclonal antibodies specific to V. cholerae O1 and/or O139.…”

mentioning

confidence: 99%

Field Evaluation of Cholkit Rapid Diagnostic Test forVibrio Cholerae O1During a Cholera Outbreak in Malawi, 2018

Chibwe

Kasambara

Kagoli

et al. 2020

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

Evaluation of the SD bioline cholera rapid diagnostic test during the 2016 cholera outbreak in Lusaka, Zambia

Cited by 19 publications

References 19 publications

<p>Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study</p>

<p>Drug Non-Adherence And Reasons Among Multidrug-Resistant Tuberculosis Patients In Guizhou, China: A Cross-Sectional Study</p>

Three transmission events of Vibrio cholerae O1 into Lusaka, Zambia

Field Evaluation of Cholkit Rapid Diagnostic Test forVibrio Cholerae O1During a Cholera Outbreak in Malawi, 2018

Contact Info

Product

Resources

About